Psychedelic substances have gained a lot of traction in recent years as an alternative treatment for various mental health conditions. However, under current FDA regulations, they are an unapproved and unavailable drug in the United States.
But as the success stories of people suffering from depression, post-traumatic stress disorder (PTSD), and other conditions continue to be publicized, there’s an ever-growing pressure on the FDA to approve psychedelics. Keep reading as we uncover the FDA’s recent position and the factors influencing approval. We also show you how to trade predictions on this real-world event at Kalshi.
A Must-Try Prediction Market Site
The Recent Stance of the FDA on Psychedelics
The interest in psychedelic medicines has grown at a rapid rate over the past few years, particularly for treating mental health, including conditions such as PTSD and depression. In 2023, the FDA began preparing for psychedelic clinical trials, signaling that the agency could be prepared to approve the drugs if the evidence is backed by scientific data.
However, in 2024, the FDA rejected Lykos Therapeutics' application for the use of MDMA to treat PTSD, as they believed there was insufficient evidence for its effectiveness. Since then, attention has shifted toward psilocybin-based treatments. In fact, in 2026, the FDA announced measures to accelerate reviews of selected psychedelic therapies. This has led many prediction traders to believe a psychedelic approval could be on the horizon.
Key Factors That Could Drive the FDA’s Approval of Psychedelics
Several factors could influence the FDA to approve psychedelics for medical use. Here are some of the most important:
- Positive late-stage clinical trial results that demonstrate strong safety and effectiveness.
- Successful FDA review process with no major concerns over trial design or quality.
- Improved safety for supervised psychedelic-assisted therapy.
- Support from independent advisory committees.
- A growing amount of scientific evidence from academic and industry research.
- Continued political and public support for psychedelics as a mental health treatment.
Recommended Prediction Market Site
How to Trade This Question at Kalshi
Kalshi is one of the
prediction market sites
where this event is available. Importantly, the contracts at this platform state that psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca. Here’s how the event is trading currently:
| Kalshi prediction market | Chance | Yes contract price | No contract price |
| Will the FDA Approve Any Psychedelic Substance for Medical Use This Year? | 35% | $0.35 | $0.69 |
You won’t be limited to this one event when trading at Kalshi. The platform offers several thousand prediction markets across sports, technology, economics, politics, culture, and more. Plus, registering with any of our links on this page gets you a $10 trading bonus.
Final Thoughts: Will Psychedelics Receive FDA Approval?
It’s unclear whether Psychedelics will ever receive FDA approval, although prediction markets currently suggest there’s a chance of around 35%. Still, there appears to be continued public support, as these drugs continue to demonstrate their effectiveness for improving mental health. If you’ve got any opinions of your own, you can now trade them at platforms such as Kalshi by using any of our links.
Don't Miss Out on This Site
Advertiser disclosure
